AllianceBernstein
DFTX

AllianceBernstein’s Definium Therapeutics DFTX Stock Holding History

AllianceBernstein’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1M Buy
1,803,287
+1,711,584
+1,866% +$42.3M 0.01% 740
2026
Q1 		$1.73M Buy
91,703
+16,866
+23% +$286K ﹤0.01% 2082
2025
Q4 		$1M Buy
74,837
+7
+0% +$87 ﹤0.01% 2339
2025
Q3 		$882K Hold
74,830
– – ﹤0.01% 2400
2025
Q2 		$486K Sell
74,830
-750
-1% -$4.93K ﹤0.01% 2652
2025
Q1 		$442K Buy
75,580
+7,650
+11% +$54.8K ﹤0.01% 2600
2024
Q4 		$473K Sell
67,930
-7,400
-10% -$50.9K ﹤0.01% 2663
2024
Q3 		$429K Hold
75,330
– – ﹤0.01% 2742
2024
Q2 		$543K Buy
+75,330
New +$659K ﹤0.01% 2630
2022
Q2 		– Sell
-19,453
Closed -$324K – 3335
2022
Q1 		$324K Buy
19,453
+73
+0.4% +$1.27K ﹤0.01% 2849
2021
Q4 		$401K Sell
19,380
-3,013
-13% -$96.2K ﹤0.01% 2829
2021
Q3 		$783K Hold
22,393
– – ﹤0.01% 2590
2021
Q2 		$1.16M Buy
+22,393
New +$1.18M ﹤0.01% 2471

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein's DFTX Position: Q2 2026 in Review

AllianceBernstein increased its Definium Therapeutics (DFTX) stake by 1,866% in Q2 2026, buying an estimated $42.3M and bringing the position to 1,803,287 shares worth $34.1M. The position accounts for 0.01% of the portfolio, ranked #740.

AllianceBernstein first reported a position in DFTX in Q2 2021 and has held it in 13 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • AllianceBernstein held 1,803,287 shares of Definium Therapeutics worth $34.1M as of Q2 2026.
  • AllianceBernstein bought 1,711,584 Definium Therapeutics shares in Q2 2026, an estimated $42.3M.
  • Definium Therapeutics made up 0.01% of AllianceBernstein's portfolio in Q2 2026, its #740 holding.
  • AllianceBernstein first reported a position in Definium Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.